摘要
Introduction. Semaglutide is an effective glucagon-like peptide 1 (GLP-1) receptor agonist for obesity, but direct comparative evidence between weekly injectable and high-dose oral formulations remains limited. This study compared the effectiveness, tolerability, and adherence of injectable semaglutide 2.4 mg once weekly versus oral semaglutide 50 mg once daily in adults with obesity. Material and methods. In this prospective, open-label, real-world comparative effectiveness study, 240 adults with BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with an obesity-related comorbidity received injectable semaglutide or oral semaglutide according to nonrandomized allocation based on routine clinical decision-making and patient treatment preference, both with structured lifestyle intervention, for 68 weeks. The primary endpoint was percentage body-weight change from baseline to week 68. Secondary endpoints included categorical weight-loss responses, BMI, waist circumference, HbA1c, systolic blood pressure, adherence, and adverse events. Results. Mean percentage weight loss was greater with injectable semaglutide than with oral semaglutide (−14.7 ± 4.9% vs. −13.3 ± 5.7%; adjusted between-group difference, −1.4 percentage points (95% CI −2.7 to −0.1); p = 0.033). Weight loss ≥ 15% occurred in 47.5% vs. 33.3% and weight loss ≥ 20% in 15.8% vs. 12.5%, respectively. Both groups showed clinically meaningful reductions in BMI, waist circumference, HbA1c, and systolic blood pressure. Gastrointestinal adverse events were common but generally mild; adherence was higher with weekly injectable therapy. Conclusions. In this prospective comparative effectiveness study, injectable semaglutide produced modestly greater weight reduction and adherence, whereas oral semaglutide remained a clinically effective noninjectable option. Route preference, adherence capacity, tolerability, and availability should guide individualized obesity pharmacotherapy.